The SARS-Risk Project is funded by CDC and proposes to determine the epidemiology and risk factors for secondary infection and recovery of antibiotic resistance (AR) or fungal organisms among Coronavirus Disease 2019 (COVID-19) patients.  It is hypothesized that COVID-19 patients have a substantial risk for hospital-acquired infection. The impact of COVID-19 on antimicrobial use also is not well described but likely is intense and may contribute to AR. This project aims to further understand these questions and it is conducted at three hospitals, all part of the Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN).

 

The participating sites will leverage the CAPriCORN common data model (CDM) and supplemented with data that are of interest for this project, such as mechanical ventilator use information. MRAIA serves as the multicenter research coordinator. MRAIA manages the project progress, produces reports to project funders, and conducts data aggregation, analysis, and visualization.

​